ArticleScientific reports2020
A negative covariation between toxoplasmosis and CoVID-19 with alternative interpretations.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Frequency of exposure to Toxoplasma gondii in COVID-19 patients: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- Anti-Toxoplasma gondii IgG seroprevalence in the general population in Iran: A systematic review and meta-analysis, 2000-2023.PloS one · 2024Pooled it
- Small but threatening: Punctate Outer Retinal Toxoplasmosis (PORT), a case series report.PLoS neglected tropical diseases · 2025Observational
- Long-term immune changes after COVID-19 and the effect of BCG vaccination and latent infections on disease severity.Clinical & translational immunology · 2025Article
- Sero-prevalence of Toxoplasma gondii before and during the COVID-19 pandemic in Northwestern Iran.BMC infectious diseases · 2024Article
- Impact of latent toxoplasmosis on pneumonic and non-pneumonic COVID-19 patients with estimation of relevant oxidative stress biomarkers.Folia parasitologica · 2024Article
- Genetic diversity and seroprevalence of Toxoplasma gondii in COVID‑19 patients; a first case-control study in Iran.BMC infectious diseases · 2024Article
- Country's value priorities in health crisis: How dominant societal motivations shape COVID-19 severity.SSM - population health · 2023Article
- Article
- Beyond the surface: accounting for confounders in understanding the link between collectivism and COVID-19 pandemic in the United States.BMC public health · 2023Article
- Association of Toxoplasmosis and COVID-19 in a MexicanPopulation.Microorganisms · 2023Article
- Heightened religiosity proactively and reactively responds to the COVID-19 pandemic across the globe: Novel insights from the parasite-stress theory of sociality and the behavioral immune system theory.International journal of intercultural relations : IJIR · 2022Article
- The role of polyspecific T-cell exhaustion in severe outcomes for COVID-19 patients having latent pathogen infections such as Toxoplasmagondii.Microbial pathogenesis · 2021Article
- Effects of dietary nucleotides and cationic peptides on vaccination response in cats.Veterinarni medicina · 2021Article
- A simple method to describe the COVID-19 trajectory and dynamics in any country based on Johnson cumulative density function fitting.Scientific reports · 2021Article
- The role of ingroup assortative sociality in the COVID-19 pandemic: A multilevel analysis of google trends data in the United States.International journal of intercultural relations : IJIR · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 5 countries.
Funding
Abstract
Coronaviruses may exert severely negative effects on the mortality and morbidity of birds and mammals including humans and domestic animals. Most recently CoVID-19 has killed about half million people (27th of June, 2020). Susceptibility to this disease appears to differ markedly across different societies but the factors underlying this variability are not known. Given that prevalence of toxoplasmosis in human societies may serve as a proxy for hygiene, and it also exerts both direct and immune-mediated antiviral effects, we hypothesize a negative covariation between toxoplasmosis and measures of the CoVID-19 pandemic across countries. We obtained aged-adjusted toxoplasmosis prevalence of pregnant women from the literature. Since the differences in the CoVID-19 morbidity and mortality may depend on the different timing of the epidemics in each country, we applied the date of first documented CoVID-19 in each country as a proxy of susceptibility, with a statistical control for population size effects. Using these two indices, we show a highly significant negative co-variation between the two pandemics across 86 countries. Then, considering that the wealth of nations often co-varies with the prevalence of diseases, we introduced GDP per capita into our model. The prevalence of toxoplasmosis co-varies negatively, while the date of first CoVID-19 co-varies positively with GDP per capita across countries. Further, to control for the strong spatial autocorrelation among countries, we carried out a Spatial Structure Analyses of the relationships between the date of first CoVID-19, prevalence of toxoplasmosis, and GDP per capita. Results of this analysis did not confirm a direct causal relationship between toxoplasmosis and susceptibility to the CoVID-19 pandemics. As far as an analysis of observational data let us to suggest, it appears that the interaction between CoVID-19 and toxoplasmosis is mediated by GDP per capita and spatial effects. This prompts the question whether the formerly known covariations of CoVID-19 and BCG vaccination or air pollution might have also emerged as spurious indirect effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.